Section of Gastroenterology, Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
Therap Adv Gastroenterol. 2012 Sep;5(5):275-83. doi: 10.1177/1756283X11417037.
Spontaneous bacterial peritonitis (SBP) is associated with a high mortality rate. After antibiotic therapy, improvement in fluid polymorphonuclear (PMN) cell count is expected within 2 days. However, our institution recognized cases unresponsive to standard treatment.
To study these recalcitrant cases, we completed a retrospective chart review of patients admitted for SBP to the University of Chicago from 2002 to 2007. SBP was defined by an ascitic PMN cell count ≥250/ml.
Of 55 patients with SBP, 15 did not show improvement in fluid PMN cell count to below 250/ml with standard treatment, leading to a prevalence of 27%. The patients with persistent SBP were younger than those with nonpersistent SBP [mean (SD) 51.80 (9.84) compared with 58.13 (8.79); p = 0.0253]. Persistent SBP had a higher serum ascites albumin gradient (SAAG) [median (Q1, Q3) 1.85 (1.50, 2.41) compared with 1.10 (0.60, 1.60)] and a higher score in the model for end-stage liver disease (MELD) [mean (SD) 27.98 (8.09) compared with 22.22 (8.10)] than nonpersistent SBP patients; p = 0.027 and p = 0.023, respectively. In addition, persistent SBP patients were more likely to have a positive ascitic fluid culture than nonpersistent SBP patients [odds ratio (OR) (95% CI) 4.33 (1.21, 15.47); p = 0.024]. Importantly, in-hospital mortality in the persistent SBP group was 40%, compared with 22.5% in the nonpersistent SBP group [OR = 2.30 (0.64, 8.19); p = 0.20].
The risk of persistent SBP is nearly 40% in patients with MELD score >25, SAAG >1.5 or positive ascitic fluid culture. Furthermore, patients who develop persistent SBP tend to experience a higher mortality rate. This study underscores the importance of further examination of this vulnerable population.
自发性细菌性腹膜炎(SBP)与高死亡率相关。抗生素治疗后,预计体液中多形核白细胞(PMN)计数的改善将在 2 天内发生。然而,我们机构发现了一些对标准治疗无反应的病例。
为了研究这些难治性病例,我们对 2002 年至 2007 年期间因 SBP 入住芝加哥大学的患者进行了回顾性图表审查。SBP 通过腹水 PMN 细胞计数≥250/ml 来定义。
在 55 例 SBP 患者中,有 15 例在标准治疗下,PMN 细胞计数未降至 250/ml 以下,发生率为 27%。持续性 SBP 患者比非持续性 SBP 患者更年轻[平均(标准差)51.80(9.84)与 58.13(8.79);p=0.0253]。持续性 SBP 的血清腹水白蛋白梯度(SAAG)更高[中位数(Q1,Q3)1.85(1.50,2.41)与 1.10(0.60,1.60)],终末期肝病模型(MELD)评分也更高[平均值(标准差)27.98(8.09)与 22.22(8.10)];p=0.027 和 p=0.023。此外,持续性 SBP 患者腹水培养阳性的可能性高于非持续性 SBP 患者[比值比(OR)(95%置信区间)4.33(1.21,15.47);p=0.024]。重要的是,持续性 SBP 组的住院死亡率为 40%,而非持续性 SBP 组为 22.5%[OR=2.30(0.64,8.19);p=0.20]。
MELD 评分>25、SAAG>1.5 或腹水培养阳性的患者,持续性 SBP 的风险接近 40%。此外,发生持续性 SBP 的患者更有可能经历更高的死亡率。本研究强调了进一步检查这一脆弱人群的重要性。